Compare Baxter International Inc (BAX) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Kimberly Clark Corp — how do they compare? Baxter International Inc trades at $27.03 (market cap $14.27B), while Kimberly Clark Corp trades at $109.19 (market cap $36.11B). The key difference: Kimberly Clark Corp is far larger — about 2.5× Baxter International Inc's market cap, and Kimberly Clark Corp pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| BAX | KMB | |
|---|---|---|
Market Cap | $14.27B | $36.11B |
Sector | Health | Consumer Staples |
52-Week High | $28.35 | $134.81 |
52-Week Low | $15.80 | $93.05 |
Enterprise Value | $21.79B | $41.67B |
Dividend Yield | 0.14% | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International Inc. (BAX) trades at $27.78, up 0.83% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.56 versus $0.37 expected, and revenue guidance was raised, signaling operational improvement. However, the company posted a net loss of -$957 million in 2025, with negative profit margins and high P/E of 87.85, reflecting valuation concerns amid turnaround efforts.
The stock shows potential from earnings momentum and cost initiatives, but high debt and inconsistent profitability pose risks. Analyst consensus is mixed with a $25.43 price target below current levels, suggesting cautious optimism. Investors should weigh recent beats against structural challenges in the medtech sector.
Kimberly-Clark (KMB) trades at $108.02, down 1.51% today, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings missed expectations, prompting a lowered 2026 outlook due to China diaper market weakness and North American volatility. The company maintains strong profitability with a net income margin of 11.79% and a high ROE of 129.43%, but faces revenue pressure with 2025 sales at $16.45B, down from prior years. Dividend payments remain steady at $1.28 per share, supporting income investors.
KMB presents a cautious outlook with near-term headwinds overshadowing long-term strengths. Investment opportunities include a discounted valuation relative to historical levels and a reliable dividend yield. Key risks involve execution challenges in China, competitive pressures, and macroeconomic sensitivity. Analyst consensus is mixed, with a $113.20 price target suggesting modest upside, but investors should weigh operational uncertainties against the company's brand resilience and cost-saving initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
